Adage Capital Partners
EGRX

Adage Capital Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Adage Capital Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500,000
Closed -$7.88M – 949
2023
Q3 		$7.88M Buy
500,000
+100,000
+25% +$1.8M 0.02% 611
2023
Q2 		$7.78M Hold
400,000
– – 0.02% 609
2023
Q1 		$11.3M Hold
400,000
– – 0.03% 590
2022
Q4 		$11.7M Buy
400,000
+150,000
+60% +$4.77M 0.03% 596
2022
Q3 		$6.61M Hold
250,000
– – 0.02% 743
2022
Q2 		$11.1M Buy
+250,000
New +$11.5M 0.03% 643
2018
Q3 		– Sell
-50,000
Closed -$3.78M – 769
2018
Q2 		$3.78M Buy
+50,000
New +$3.15M 0.01% 669
2016
Q3 		– Sell
-20,000
Closed -$776K – 736
2016
Q2 		$776K Buy
+20,000
New +$833K ﹤0.01% 665

Other funds holding EGRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return